David Hunt

David Hunt

Auto-generated profile, based on publicly available information

David Hunt

Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK; UK DRI University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MRMathieu P. Rodero
Mathieu P. Rodero
JDJérémie Decalf
Jérémie Decalf
VBVincent Bondet
Vincent Bondet
DHDavid Hunt
David Hunt
GRGillian I. Rice
Gillian I. Rice
DDDarragh Duffy
Darragh Duffy
Type I interferons (IFNs) are essential mediators of antiviral responses. These cytokines have been implicated in the pathogenesis of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermatomyositis, as well as monogenic type I interferonopathies. Despite a fundamental role in health and disease, the direct quantification of type I IFNs has been challenging. Using single-molecule array (Simoa) digital ELISA technology, we recorded attomolar concentrations of IFNα in healthy donors, viral infection, and complex and monogenic interferonopathies. IFNα protein correlated well with functional activity and IFN-stimulated gene expression. High circulating IFNα levels were associated with increased clinical severity in SLE patients, and a study of the cellular source of IFNα protein indicated disease-specific mechanisms. Measurement of IFNα attomolar concentrations by digital ELISA will enhance our understanding of IFN biology and potentially improve the diagnosis and stratification of pathologies associated with IFN dysregulation.

25 October 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MPMartina Patone
Martina Patone
LHLahiru Handunnetthi
Lahiru Handunnetthi
DSDefne Saatci
Defne Saatci
JPJiafeng Pan
Jiafeng Pan
SKSrinivasa Vittal Katikireddi
Srinivasa Vittal Katikireddi
JHJulia Hippisley-Cox
Julia Hippisley-Cox
Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). There was an increased risk of Guillain–Barré syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15–3.92 at 15–21 days after vaccination) and Bell’s palsy (IRR, 1.29; 95% CI: 1.08–1.56 at 15–21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12–1.71 at 15–21 days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain–Barré syndrome (IRR, 2.32; 95% CI: 1.08–5.02 at 1–28 days). There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain–Barré syndrome (IRR, 5.25; 95% CI: 3.00–9.18). Overall, we estimated 38 excess cases of Guillain–Barré syndrome per 10 million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test.

4 March 2021 in Science Immunology
Verified
Journal Article
Open access
PDF file
RTRyan S Thwaites
Ryan S Thwaites
AUAshley Sanchez Sevilla Uruchurtu
Ashley Sanchez Sevilla Uruchurtu
MSMatthew K Siggins
Matthew K Siggins
FLFelicity Liew
Felicity Liew
CRClark D Russell
Clark D Russell
POPeter JM Openshaw
Peter JM Openshaw
GM-CSF is elevated early, scaled with severity, and is central to the inflammatory response in COVID-19, but not severe influenza.

15 December 2016 in Blood
Verified
Journal Article
Open access
PDF file
DKDavid Kavanagh
David Kavanagh
SMSarah McGlasson
Sarah McGlasson
AJAlexa Jury
Alexa Jury
JWJac Williams
Jac Williams
Neil J. ScoldingNeil J. Scolding
Neil J. Scolding
DHDavid P. J. Hunt
David P. J. Hunt
Key Points: Type I IFN therapies can cause a dose-dependent TMA. Recombinant type I IFN therapies should be stopped at the earliest opportunity in patients who develop TMA.

6 June 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
SMSarah McGlasson
Sarah McGlasson
SWStewart Wiseman
Stewart Wiseman
JWJoanna Wardlaw
Joanna Wardlaw
NDNeeraj Dhaun
Neeraj Dhaun
DHDavid P. J. Hunt
David P. J. Hunt
The brain and nervous system are important targets for immune-mediated damage in systemic lupus erythematosus (SLE), resulting in a complex spectrum of neurological syndromes. Understanding and classifying nervous system disease in lupus pose significant challenges. Among the difficulties to be addressed are a diversity of clinical manifestations and a lack of understanding of their mechanistic basis. However, despite these challenges, progress has been made in our understanding of the pathways which contribute to neurological disease in SLE. Understanding the molecular pathogenesis of neurological disease in lupus will inform both classification and approaches to clinical trials.

14 June 2024 in Immunity
Verified
Journal Article
Open access
BVBarney Viengkhou
Barney Viengkhou
EHEmina Hayashida
Emina Hayashida
SMSarah McGlasson
Sarah McGlasson
KEKatie Emelianova
Katie Emelianova
DFDeborah Forbes
Deborah Forbes
Markus HoferMarkus Hofer
Markus Hofer
Aicardi-Goutières syndrome (AGS) is an autoinflammatory disease characterized by aberrant interferon (IFN)-α production. The major cause of morbidity in AGS is brain disease, yet the primary source and target of neurotoxic IFN-α remain unclear. Here, we demonstrated that the brain was the primary source of neurotoxic IFN-α in AGS and confirmed the neurotoxicity of intracerebral IFN-α using astrocyte-driven Ifna1 misexpression in mice. Using single-cell RNA sequencing, we demonstrated that intracerebral IFN-α-activated receptor (IFNAR) signaling within cerebral endothelial cells caused a distinctive cerebral small vessel disease similar to that observed in individuals with AGS. Magnetic resonance imaging (MRI) and single-molecule ELISA revealed that central and not peripheral IFN-α was the primary determinant of microvascular disease in humans. Ablation of endothelial Ifnar1 in mice rescued microvascular disease, stopped the development of diffuse brain disease, and prolonged lifespan. These results identify the cerebral microvasculature as a primary mediator of IFN-α neurotoxicity in AGS, representing an accessible target for therapeutic intervention.